---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-032181"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:17:14.414186+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# INVO Bioscience Q2 2024 revenue surged 481% to $1.84M; adjusted EBITDA improved by $1.1M to $(0.5)M

## Summary
- Revenue $1,836,597, up 481% YoY ($315,902); clinic revenue up 611% to $1,807,921.
- Net loss remained $(2.2) million; total operating expenses rose to $3.7M, including $1.0M non-cash expense.
- Adjusted EBITDA improved to $(0.5) million from $(1.6) million in Q2 2023.
- All three fertility centers (Middleton, Atlanta, Birmingham) reported sequential revenue growth and are collectively profitable.
- Merger with NAYA Biosciences (all-stock) still in discussions for further extension; $25K in transaction costs incurred in Q2.

## SEC filing metadata
- accession: 0001493152-24-032181
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315224032181/0001493152-24-032181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315224032181/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-032181
- JSON: https://secwatch.observer/filing/0001493152-24-032181.json
- Plain text: https://secwatch.observer/filing/0001493152-24-032181.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.